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Abstract 
Background: The human papillomavirus (HPV) is a preventable, sexually transmitted 
infection. The vaccines for HPV are safe and effective, but previous research demonstrated that 
nursing students have low knowledge levels and vaccine uptake. Low knowledge and attitude 
levels in nurses and nurse practitioners can influence parental and patient decision making for 
HPV vaccination. Purpose: The purpose of this scholarly project was to evaluate HPV 
knowledge and attitudes and their association with vaccination uptake in college nursing 
students. There is limited research in the United States on HPV knowledge, attitudes, and uptake 
of the vaccine among nursing students. Methods: This project was a replication study utilizing 
an anonymous, cross-sectional, online survey methodology to measure the HPV knowledge, 
attitudes, and uptake of the vaccine in nursing students. The survey was given to a convenience 
sample of undergraduate and graduate nursing students (n = 447) at a private, liberal arts 
university. Results: Nursing students had high knowledge and attitude scores. While there were 
no significant differences between knowledge between genders (p = .59), there were differences 
in knowledge between undergraduate and graduate students (p < .001). There were no 
differences in attitude between genders and student classification. Knowledge was not associated 
with uptake (p = .63), but there was an association between attitudes and uptake 
(p <.001). Conclusion: This study supported that nursing students have high knowledge and 
attitude levels towards HPV and HPV vaccination, which may lead to improved vaccination 
uptake in the future. 
 
Keywords: HPV infection, papillomavirus vaccines, nurses, vaccinations, health 
knowledge, student health, knowledge, attitudes 
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Introduction and Background 
The human papillomavirus (HPV) is one of the most common sexually transmitted 
diseases in the world. HPV affects about 79 million Americans, with the majority in their late 
teens or early twenties (Centers for Disease Control and Prevention [CDC], 2017). In the past, 
HPV was one of the leading causes of deaths for women in the United States due to cervical 
cancer. Incidence rates for cervical cancer have decreased over last 20 years. From 2011 to 2016, 
the rate has decreased by 29% for women ages 15 to 24 years old and 13% for women ages 25 to 
34 due to increased emphasis on HPV vaccine and routine cervical cancer screening (Guo, Cofie, 
& Berenson, 2018).  
HPV was found to be the cause of 79% of the 44,000 yearly cases of HPV-related 
cancers (Saraiya et al., 2015). Exposure to HPV causes an increased risk for cervical, oral, 
penile, vaginal, anal, oropharyngeal cancers and warts. For females, the most common HPV-
related cancer is cervical cancer (48.6%) followed by anal (17.6%), vulvar (16.2%), and 
oropharyngeal cancer (14.0%) (CDC, 2019a). Although there has been a significant decline in 
cervical cancer rates over the past several decades, rates for HPV-related squamous cell 
carcinoma of the oropharynx, anus, and vulva have increased (Van Dyne et al., 2018). The 
prevention of HPV tends to focus on females, but males are also at risk for the development of 
HPV cancer. For males, the most common HPV-related cancer is oropharyngeal cancer (81.3%) 
followed by anal (11.9%) and penile cancer (6.8%) (CDC, 2019a).  Although penile cancer is 
rare (0.69 per 100,000 men), rates have slightly increased worldwide (Kidd et al., 2017). HPV is 
found in half of all penile cancers (American Cancer Society, 2018). These conditions may be 
preventable with HPV vaccination.  Approximately 51.1% of American adolescents are up to 
date on the HPV series, but this is still below the national target goal of 80% for adolescents that 
HPV VACCINATION 
 
7 
up to date on HPV vaccination (Healthy People 2020, 2019; Walker et al., 2019). Over half 
(68.1%) of American adolescents have had at least one dose of the HPV series, but, about 35% 
have completed the series by age 15 (Bednarcyzyk, Ellingson, & Omer, 2019; Walker et al., 
2019).  
HPV 
HPV is a sexually transmitted disease associated with genital warts and increased risks of 
certain cancers (CDC, 2019b). There are more than 200 types of HPV, which are divided into 
low-risk and high-risk classifications. Low-risk HPV types are more likely to cause genital, anal, 
and oral warts, and high-risk HPV types are more likely to cause cervical, vaginal, vulvar, anal, 
penile, and oropharyngeal cancer. Of the 14 high-risk types that can cause cancer, types 16 and 
18 cause 70% of pre-cervical lesions and cancers (CDC, 2019b). 
HPV-related cancers are easily preventable through immunization and routine cervical 
cancer screening. Eighty percent of the population will be infected with HPV at least once during 
their lifetime, and in most cases, one’s immune system can overcome the infection without 
complications (CDC, 2019c). Cervical cancer is the only type of HPV-related cancer with a 
recommendation for routine screening. Since there are no other screenings for other types of 
HPV-related cancers and may be undetected for years until symptoms appear, it is even more 
important to encourage patients to prevent cancer through immunization.  
HPV Vaccines 
The CDC recommends the vaccine for males and females age 11 to 12, but the vaccine 
may be given as early as nine years old. Females up to age 26 and for males up to age 21 are 
eligible to be vaccinated. Although the United States Federal Food and Drug Administration 
(FDA) (2018) approved the vaccine for all persons up to age 45 for Gardasil 9, the CDC only 
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recommends vaccination for adults age 27 to 45 if they are at a higher risk for infection (Meites 
et al., 2019). Adolescents who receive the vaccination between the age of nine to 14 are eligible 
to receive the two-dose vaccine six months apart. Those who initiate the vaccine at ages 15 or 
older are recommended to receive the three-dose vaccine. Immunocompromised persons nine to 
26 years old are also recommended to have the three-dose vaccine.  
There are three HPV vaccines approved for use in the United States: Cervarix, Gardasil, 
and Gardasil 9. GlaxoSmithKline manufactures Cervarix, and it prevents infections from HPV 
16 and 18. Merck & Co. manufacture Gardasil and Gardasil 9. Gardasil prevents infections from 
types 6, 11, 16, 18. However, Gardasil 9 is broader in coverage and prevents types 6, 11, 16, and 
18 as well as five other types that cause 20% of cancers (types 31, 33, 45, 52, and 58).  If the 
HPV vaccine for 16 and 18 (Cervarix) covered 100% of the population, then 63.4% (24,548) of 
HPV cancer cases (24,548) could be prevented annually and an additional 10% of cases (3,944) 
if the 9-valent vaccine were given (Saraiya et al., 2015). These results are agreeable with a 
previous meta-analysis from two international HPV vaccine studies (Serrano, 2012). In 2018, 
51.1% of adolescents were up-to-date on HPV vaccinations, with 68.1% of the adolescent 
population has received at least one dose (Walker et al., 2019). Even though the vaccination rate 
has increased, only 35% of adolescents 15 or older have completed the series (Bednarcyzyk et 
al., 2019). This is still below the national target goal of 80% (Healthy People 2020, 2019). 
One of the key interventions to prevent the spread of HPV and HPV morbidity and 
mortality is the uptake of the HPV vaccination. In the United States, there are about 33,700 men 
and women who have HPV cancer, but with the vaccine, 32,100 cases could be prevented (CDC, 
2019b). Nurses and Advanced Practice Registered Nurses (APRNs) are in a remarkable position 
to educate patients, parents, and the community on HPV and vaccination. Patients expect nursing 
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professionals to have sound knowledge and understanding if they have questions about the 
vaccine. However, there have been few studies focusing solely on the knowledge and attitudes of 
HPV and the vaccinations in nursing students (Schmotzer & Reding, 2013). 
Among the general undergraduate college student population, there are poor knowledge 
and attitudes of HPV and the vaccine. Even more so, there are low rates of HPV vaccine uptake. 
As future healthcare workers, nursing students are expected to have higher knowledge levels 
regarding HPV, but there is limited research available on nursing students’ knowledge and 
attitudes regarding this topic (Schmotzer & Reding, 2013). The lack of information on American 
nursing students’ knowledge and attitudes and uptake of the vaccine supports the need for further 
research on the topic. 
Problem Statement 
           While there have been many studies on general college students and HPV, there is a gap 
in the literature on knowledge and attitudes of HPV and the uptake of the HPV vaccine among 
college nursing students. 
Purpose 
           The purpose of this scholarly project was to evaluate HPV knowledge and attitudes, and 
their association to vaccination uptake in college nursing students.  
Research Questions 
In consideration of the project’s purpose to assess HPV knowledge, attitudes, and uptake 
in nursing students, the project aimed to focus on the following four questions:  
1. What is the knowledge level of undergraduate and graduate nursing students? 
2. What are the attitudes of undergraduate and graduate nursing students? 
3. What is the vaccine uptake rate among undergraduate and graduate nursing students? 
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4. How do knowledge and attitudes affect uptake in undergraduate and graduate nursing 
students? 
Hypotheses 
           Based on previous findings in the college population and nursing students, the project 
leader hypothesized low knowledge levels in undergraduate and graduate nursing students. Due 
to their health care background and training, the project leader also hypothesized there will be a 
favorable attitude toward HPV vaccination. The author hypothesized there will be low uptake of 
the HPV vaccine among undergraduate and graduate students which is comparable to literature 
findings. 
Review of Evidence 
Previous studies investigated the impact of knowledge and attitudes on the uptake in 
college students (Beshers, Murphy, Fix, & Mahoney, 2015; Cunningham-Erves & Talbot, 2015; 
Stephens, Tamir, & Thomas, 2016; Barnard, George, Perryman, & Wolff, 2017; Kasymova, 
Harrison, & Pascal, 2019). These studies have focused on a single gender, both biological 
genders, or minorities. However, to date, there is only one study since 2013 that has explored 
knowledge and attitudes in American nursing students and their relationship to HPV vaccination 
uptake, but only focused on the differences between ethnicities (Schmotzer & Reding, 2013). 
Due to the limited amount of research among American college nursing students regarding this 
topic, the discussion will also generalize the knowledge, perceptions, and uptake of the influenza 
vaccine to support the review of the literature. 
Knowledge 
           American college students were shown to be aware of HPV but have more deficient 
knowledge levels of HPV and HPV vaccination. In studies sampling female students, poor 
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knowledge levels were attributed to misinformation or lack of knowledge of HPV and the 
vaccine (Licht et al., 2010; Beshers, et al., 2015; Zhang, Tsark, Campo, & Teti, 2015; Stephen, 
Tamir, & Thomas, 2016; Kasymova, Harrison, & Pascal, 2019; Kellogg et al., 2019). Females 
tended to know more than males about HPV, and females that were vaccinated were more likely 
to have higher knowledge levels. Males were revealed to be less aware than women about HPV 
and also have weaker knowledge levels (Katz, Krieger, & Robert, 2012; Beshers, et al., 2015; 
Cunningham-Erves, & Talbot, 2015; Johnson & Ogletree, 2017). Poor knowledge levels among 
men may be influenced by several factors, such as the belief that HPV vaccination is only for 
women, the lack of visible symptoms when males are positive for HPV, and the lack of routine 
male HPV screening (Kasymova et al., 2019; Fontenot, Fantasia, Charyk, & Sutherland, 2014). 
Most college students are aware of HPV, but they lack knowledge about the prevalence of HPV 
in the general population and its association with diseases (Kasymova et al., 2019). 
Schmotzer and Reding's (2013) study with American nursing students revealed that 
students with inaccurate HPV knowledge were more likely to be vaccinated or intended to be 
vaccinated.  For example, those who were vaccinated were more likely to believe that HPV 
caused herpes and did not cause cervical or anal cancer. This group also did not know that the 
HPV vaccine was also for men. One study indicated undergraduate nursing students have poorer 
vaccine-related knowledge, with 24.7% having high knowledge scores as compared to medical 
(74.3%), pharmacy (62.7%), and doctoral nursing students (57.1%) (Dysband, Hall, & Carson, 
2019). It is important to educate and train all nursing students to understand the importance of 
vaccination. Those with poorer knowledge levels may not have had education or may need 
reeducation on HPV and the HPV vaccine. The knowledge they share can impact a patient’s or a 
parent’s decision to vaccinate for HPV.   
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Attitudes  
           Positive attitudes towards vaccination were associated with uptake of the vaccine, and 
women tended to have more favorable attitudes toward vaccination (Barnard et al., 2017). 
Findings in the literature showed females have low levels of perceived HPV severity and risk, 
perceived HPV vaccine safety, and perceived social approval (Marchand, Glenn, & Bastani, 
2012; Stephens, Tamir, & Thomas, 2016). Generally, males tended to have lower perceived risk 
as compared to women. However, if there was an increased risk due to risky sexual behavior or 
practices, they were more willing to consider vaccination (Katz et al., 2012; Fontenot et al., 
2014; Johnson & Ogletree, 2017). In several studies, males were less likely to consider 
vaccination (Fontenot et al., 2014; Barnard et al., 2017; Kasymova et al., 2019).   
Nurses’ attitudes toward vaccination play a significant role in influencing patients. The 
bedside or clinic nurse most often meets the patient before the provider. This meeting can set the 
tone for the parents’ or the patient’s decision to receive the HPV vaccine. Schmotzer and Reding 
(2013) did not address attitudes in their study of nursing students towards HPV. One study 
revealed that undergraduate nursing students were more hesitant, less likely to recommend, and 
had less confidence in recommending vaccinations in general (Dysband et al., 2019). However, 
doctorate nursing students were more confident at discussing vaccines with patients than medical 
and pharmacy students. Limiting the concerns and barriers to vaccination among nurses may 
result in favorable attitudes towards HPV vaccination and recommendation.   
Uptake 
           Across the literature, 25% to 68.8% of college females and 0% to 52% of college males 
were up-to-date on HPV vaccination (Schmotzer & Reding, 2013; Richman, Maddy, Torres, & 
Goldberg, 2016; Barnard et al., 2017; Johnson & Ogletree, 2017) Younger students were more 
HPV VACCINATION 
 
13 
likely to receive the HPV vaccine, which may be due to the effects of the vaccine being released 
in 2006 (Thompson et al., 2017). In nursing students, less than half (28.9%) of the respondents 
reported receiving the vaccine (Schmotzer & Reding, 2013). For participants who have not 
started the vaccine series or have not completed it, it is recommended to start or complete the 
vaccination process for all students to prevent consequences of HPV and transmission of the 
virus to others. 
Other Influencers to Uptake 
           Barriers. Other barriers to HPV vaccination are mentioned in the literature. The most 
frequent concerns were logistics, cost, insurance, stigma, and fear of side effects (Katz et al., 
2012; Stephens et al., 2016; Martin et al., 2018; Kasymova et al., 2019). Logistics included 
waiting time and transportation to a clinic if the vaccine was not offered on campus. Younger 
college students may rely on their parents for finances, insurance, and may be embarrassed to ask 
them to pay for the vaccination due to perceived sexual stigma (Katz et al., 2012; Martin et al., 
2018). Other historical and current barriers to HPV vaccination uptake are moral and religious 
reasons against the vaccine (Vamos, McDermott, & Daley, 2008). 
           Facilitators. Facilitators to HPV vaccination uptake are recommendations from the 
provider, parental influence, increased communication, and perceived risk of HPV (Barnard et 
al., 2017; Katz et al., 2012; LaJoie, Kerr, Clover, & Harper, 2018; Marchand et al., 2012; 
Stephens, Tamir, & Thomas, 2016). A health care provider’s recommendation is one of the 
strongest predictors for the uptake of the vaccine (Gilkey et al., 2016; Kellogg et al., 2019). 
Students prefer to receive knowledge from a provider due to their credibility and expertise on 
this topic (Lanning, Golman, and Crosslin, 2017). Although parents no longer make medical 
decisions for the majority of college students, parental influence may continue to play a role in 
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some young adults as college students learn to become independent (LaJoie et al., 2018). 
Providing proper education about HPV and the HPV vaccine to parents and students is an 
appropriate intervention. Some interventions used to increase communication and awareness of 
HPV vaccination are electronic medical record notifications for the providers, provider 
education, and social media prompts (Richman et al., 2016; Lanning et al., 2017; Vorsters et al., 
2017; Zhang et al., 2017). 
Currently, there is one study since 2013 on the knowledge and attitudes and uptake of the 
HPV vaccine in American nursing students (Schmotzer & Reding, 2013). Research indicates 
there are poor knowledge levels concerning HPV and the HPV vaccine. More information is 
required to assess nursing students' knowledge and attitudes on these topics. Generally, there are 
favorable attitudes towards the benefits of vaccination, but undergraduate nursing students were 
more hesitant to recommend and inform patients about the purpose, safety, and efficacy of 
vaccination (Dysband et al., 2019). Students may not have the knowledge or the confidence to 
explain this information to patients and may feel they are imposing on the primary nurse’s 
influence on the patient. Also, in Schmotzer and Reding's (2013) study, both male and female 
students had a low perceived risk of HPV.  
Overall, it appears that undergraduate nursing students scored low in knowledge, 
attitudes, and confidence. By addressing misconceptions, removing barriers, and improving the 
facilitators, there is an excellent opportunity to increase the knowledge and confidence in 
educating patients on this topic. Implications for the nursing students surpass the conclusion of 
this project. As future nurses, undergraduate nursing students can influence and inform patients 
of HPV and the overall benefits of the vaccine. Graduate nurse practitioner students will become 
APRNs who educate, provide anticipatory guidance to parents, and encourage vaccination 
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scheduling adherence to parents and patients. Because nurses tend to have more contact with the 
patients than any other health care worker, current and correct knowledge, improving 
misconceptions, and encouraging our young patients and parents on vaccination is key to 
preventing consequences of HPV and transmission to others.  
Theoretical Model 
           The Precautionary Adoption Process Model (PAPM) is a stage theory that describes and 
explains the preventative behavior of a health issue (Weinstein, 1988; Weinstein, Sandman, & 
Blalock, 2008). Stage theories are useful in describing an individual’s willingness to engage in 
preventative behaviors. Because individuals behave differently at each stage, interventions can 
be tailored to encourage them to move from one stage to the next. PAPM is similar to the well-
known Transtheoretical Model with its five Stages of Change (pre-contemplation, contemplation, 
preparation, action, and maintenance) (Prochaska & DiClemente, 1983). With the Stages of 
Change, the model assumes the individual is aware of the health issue, but it does not include 
those that are not aware of the issue. The PAPM has a broader scope and recognizes some people 
are not aware of specific health problems. Those with no knowledge of HPV have a different set 
of obstacles compared to those who are aware of HPV and its consequences. 
PAPM differentiates itself from other stage theories through its identification of seven 
stages from a person’s awareness to actions for preventative behavior. In Stage One, the 
individual is unaware or has not heard of HPV or receiving HPV vaccination for cancer and wart 
prevention. A person moves from Stage One to Stage Two after the individual has heard about a 
health issue. In Stage Two, the individual is aware of HPV but does not act on the issue. The 
person does not consider acting because other issues may compete for personal time and 
attention (Weinstein, Sandman, and Blalock, 2008). In Stage Three, the individual is undecided 
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about receiving the HPV vaccination. The individual will move out of the action stages into 
Stage Four if there is no intention to receive the vaccine. In Stage Five, the individual decides to 
get the HPV vaccine. In Stage Six, the individual gets the HPV vaccine. In Stage Seven, the last 
stage, the individual engages in the maintenance of the preventative behavior. In this example, 
the individual would complete the HPV vaccination series and participate in routine cervical 
Papanicolaou (Pap) testing (see Figure 1 for PAPM diagram). 
By identifying the stage in which individuals reside, nurses and nurse practitioners can 
apply specific interventions for individuals at each of the stages. For example, individuals who 
are in Stage One and Stage Two would highly benefit from education on HPV and how to 
prevent the consequences of HPV through vaccination and screening. This project does not 
address Stage 1, but for participants in Stage 2 with poor knowledge levels, it would be valuable 
to educate or reinforce HPV education in this group. Health care providers can target individuals 
in Stage Three and Four by looking at barriers and facilitators to HPV vaccination. Those that 
are in Stage Five, Six, and Seven will need resources and reminders or assistance in acting in the 
maintenance of preventative behaviors. 
This scholarly project applies this model through the utilization of an online survey. 
Participants who have received zero HPV vaccinations are asked about their willingness to get 
the HPV vaccine. This question categorizes participants into the PAPM Stage Two through Stage 
Five. By identifying stages in which students most identify with, interventions can be made that 
can help them transition into the next stage. The knowledge portion of the survey may indicate 
the student classification or age groups that have poorer knowledge levels. Whether or not 
students have been vaccinated or not, improving the knowledge of HPV and the vaccines in 
those with poor knowledge will be beneficial to their practice and educating their patients. 
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Project Design 
This scholarly project was a cross-sectional, replication study utilizing an anonymous, 
online survey methodology designed to assess the knowledge and attitudes of nursing students 
towards HPV and HPV vaccination. Subjects were undergraduate and graduate nursing students 
18 or older at Belmont University. Convenience sampling of male and female nursing students 
was used for this project. The anonymous survey methodology was low risk to the subjects 
allowing it to be verified as exempt by the Belmont University Institutional Review Board. 
Clinical Setting 
The project took place at Belmont University, a private, Christian, liberal arts university 
located in the southeastern United States. The university has 6,820 undergraduate students and 
1,621 graduate students with a total of 8,441 students. About 34.6% of the students identify as 
male, and 65.4% identify as female. The racial/ethnic diversity is primarily White, non-Hispanic 
(79.5%) followed by Hispanic (5.9%); Black, non-Hispanic (5.4%); two or more races, non-
Hispanic (3.9%); Asian (2.5%); and unknown race/ethnicity or other (2.6%). At the time of this 
project, HPV vaccination was not offered through Student Health Services.  
Project Population 
 Inclusion criteria were students 18 years or older at Belmont University. Exclusion 
criteria were those less than age 18 or non-nursing majors. There were 800 undergraduate and 
graduate nursing students enrolled in the fall semester of 2019 at Belmont University. Power 
analyses were conducted using G*Power version 3.1.9.4 statistical software (Faul, Erdfelder, 
Buchner, & Lang, 2009). A sample size of 226 was needed for a moderate effect. This was 
determined with an alpha of 0.05, power of 0.8, a moderate effect size of 0.5, and an allocation 
ratio of 0.2.  
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Undergraduate students included traditional nursing students and accelerated nursing 
students. Traditional students may have started as freshmen or may be transferred from another 
school or program with the opportunity to earn a four-year Bachelor of Science in Nursing 
(BSN) degree. The accelerated track was for individuals who have previously obtained a 
Bachelor’s degree in another discipline. Of note, the undergraduate nursing program was mid-
way through a curriculum change to a concept-based model to address the vast amount of 
content taught in the undergraduate nursing program. Graduate nursing programs offered at 
Belmont are Master’s, Post-Master’s to Doctorate, BSN to Doctorate, and post-graduate APRN 
with a Family Nurse Practitioner (FNP) concentration. Depending on the student’s progress in 
the nursing program, students may or may not have received education on HPV. A survey 
question was added to indicate if they have had this content in their curriculum at the time of 
participation.  
Adolescents and young adults are typically the individuals who receive the HPV vaccine. 
Several undergraduate and graduate students will be outside the recommended age range for 
vaccination. Older students may have personal reasons for not considering it, such as being in a 
married or monogamous relationship for several years. Nevertheless, it is beneficial to know the 
knowledge levels and perceptions of all nursing students even though uptake, PAPM staging, 
and factors associated with vaccination will be skewed.  
Recruitment 
Convenience sampling was used to recruit participants for the project. Of the 800 nursing 
students, the project leader aimed to recruit approximately 226 participants for the study. 
Recruitment strategies include emailed letters, visiting classes, and speaking to students in the 
nursing building. A letter of invitation was sent by the Associate Dean of Nursing, on October 1, 
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2019. The letter invited undergraduate and graduate nursing students to participate in the survey 
(see Appendix A for the letter of invitation). The letter of invitation included the purpose of the 
survey, the approximate time to take the survey, gift card incentives, and the project leader’s 
contact information. Students could access the Qualtrics survey through a link in the email or a 
Quick Response (QR) code. The project leader also visited key classes to reach most of the 
nursing students. Potential participants received information about the project, estimated time to 
take the survey, and ways to access the survey. Printed QR codes were given to the students for 
alternate access to the survey (see Appendix B for QR codes). The project advisor also visited 
several classes with the project leader to help promote the study. Incentives for the class visits 
included candy and the chance to win one of four $25 Amazon gift cards. 
Instructions to win one of four $25 Amazon gift cards were placed at the end of the 
survey. To be placed in the drawing, participants were instructed to email a screenshot of the 
survey submission page to the project leader’s email address. This assures answers could not be 
associated with individual participants. Names were placed in an Excel spreadsheet in the order 
the email was sent. A random number generator was used for the drawing. The winners were 
notified by email with instructions where to pick up the gift card by November 15, 2019. 
Sources of Data and Data Collection Instruments 
This project replicated a survey by Barnard et al. (2017). The original survey was based 
on several previously utilized HPV surveys (Licht et al., 2010; Katz et al., 2012; Marchand et al., 
2012). Permission was granted by the author to alter the survey as needed. The project’s survey 
had a total of 53 items: seven demographic questions, 19 knowledge questions, 24 Likert 
questions, one question on vaccination uptake, one question on factors related to vaccination, and 
one question related to staging. At the beginning of the survey, a short narrative told participants 
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about the purpose of the survey, the time it takes to complete, incentives, and implied consent. 
Participants can exit the survey at any time if they do not wish to continue (see Appendix C for 
HPV survey).  
Before collection, the survey was piloted among a group of doctorate nursing students in 
their final year of graduate school. Concerns, questions, and suggestions for improvement or 
clarity by the cohort were considered for changes to the survey. Barnard et al.’s (2017) survey 
was not tested for reliability and validity. Content validity and face validity were verified by a 
content expert and the project leader’s advisor.  
Demographics. The demographic section included age, gender, student classification 
(undergraduate or graduate), ethnicity, whether or not they have received education on HPV, and 
whether or not they receive routine, preventative care. The participants’ biological gender was 
asked due to the relationship between gender and HPV. This question was placed at the end of 
the survey to prevent bias. 
Knowledge. Two content experts verified the content validity of the survey. The 
knowledge section contained 19 true or false questions regarding HPV and the vaccine. One 
question regarding condoms was removed from the original survey. Two additional questions 
were added to the knowledge section after discussion with a content expert: 1) “There are many 
types of HPV” and 2) “The HPV vaccine covers certain HPV strains.” These questions were 
added to assess if students were aware of multiple HPV types and specific HPV vaccines only 
protect for particular strains. Two questions were reversed scored. The maximum number of 
correct questions that could be acquired was 19. If 14 or more questions were correct, the 
participant was considered to have a high level of knowledge regarding HPV. Seven to 13 
HPV VACCINATION 
 
21 
questions correct answers indicated a moderate level of knowledge. If six or less questions are 
correct, the participant was considered to have a poor level of knowledge. 
Attitudes. Susceptibility and concerns (attitudes) were assessed through 24 questions on 
a one-to-five Likert Scale (1 – “Strongly Disagree,” 2 – “Disagree,” 3 – “Neutral,” 4 – “Agree,” 
and 5 – “Strongly Agree”). The original survey had 25 questions, but one question on the 
association of HPV to liver cancer was removed after discussion with the content expert. Three 
items were reverse scored. The total score of a participant was calculated by summing the 24 
items in this section with a maximum score of 120. A score of one to 41 reflected a poor attitude, 
a score a 42 to 89 reflected a moderate attitude, and a score of 90 to 120 reflects a high attitude 
level toward HPV and vaccination. Questions within this section were further classified into 
perceived susceptibility (10 items), concerns (eight items), vaccine safety (five items), and 
vaccine efficacy (one item). Perceived susceptibility had a maximum score of 50 with a score of 
one to 19 representing poor levels, 20 to 36 representing moderate levels, and 37 to 50 
representing high levels. Perceived susceptibility had a maximum score of 50 with a score of one 
to 19 representing poor levels, 20 to 36 representing moderate levels, and 37 to 50 representing 
high levels. Concerns had a maximum score of 40 with a score of one to 14 representing poor 
levels, 15 to 29 representing moderate levels, and 30 to 40 representing high levels. Vaccine 
safety had a maximum score of 25 with a score of one to eight representing poor levels, nine to 
17 representing moderate levels, and 18 to 25 representing high levels. Lastly, vaccine efficacy 
had a maximum score of 5 with a score of one to two representing poor levels, three representing 
moderate levels, and 4 to 5 representing high levels.  
Uptake. In the original study, the uptake section asked whether or not participants have 
been vaccinated for HPV. If they were not, participants were asked about their thoughts about 
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being vaccinated in the fifth section. After discussing with a content expert, participants were 
asked how many vaccine doses the participant has received (0, 1, or 2 or more). If participants 
chose “zero vaccines,” then they were prompted to the staging question. 
Staging and Factors. The fifth section determined the stage participants were in at the 
time of they answered the survey. The answers were based on the Precautionary Adoption 
Process Model (Weinstein, 1988; Weinstein, Sandman, & Blalock, 2008). The last section 
assessed influences toward vaccination (provider, family, friends, and the belief the virus or the 
vaccine can cause health problems) through a multiple select question.  
Data Collection Process/Procedures 
Data collection began on October 1, 2019 and was scheduled to end on October 31, 2019. 
On October 1, 2019, the HPV survey was sent to the students via email by the associate dean of 
nursing. This letter included the purpose of the survey, the approximate time to take the survey, 
gift card incentives, and contact information. Students were able to access the Qualtrics survey 
through a link in the email or a QR code.  
To optimize response rate, professors of undergraduate and graduate nursing classes were 
contacted in the Spring and Fall semester of 2019 for permission to speak to their students about 
the scholarly project. Professors that agreed to the visit allowed the project leader to speak to 
their class for five to ten minutes. The project leader visited the following classes during 
October: Wellness, Assessment, and Health; Perspectives; Care Management I; Care 
Management II; Transition to Graduate Nursing; Pediatrics; Nursing Leadership; Childbearing; 
and Advanced Health Assessment. These classes were chosen to reach as many nursing students 
who were in the older undergraduate curriculum, newer concept-based curriculum, and graduate 
nursing students. Potential participants received information about the project, estimated time to 
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take the survey, and ways to access the survey. Printed QR codes were given to the students. 
Incentives for the class visits included candy and the chance to win one of four $25 Amazon gift 
cards. The project advisor also visited several classes with the project leader to help promote the 
study. If time allowed, the students were able to take the survey during class time. In between 
classes, the project leader recruited students in the lobby and hallways of the nursing building. 
Because the response rate was greater than 50%, the survey ended early on October 23, 2019, 
with approval from the project leader advisor.  
Data Analysis. Data was downloaded into an Excel spreadsheet and transferred to SPSS 
Statistics 19.0. An alpha level of 0.05 was used to determine statistical significance. Independent 
variables were demographic information, knowledge, attitudes, stage in PAPM, and factors 
associate with uptake. The dependent variable was the uptake of the HPV vaccine. 
Descriptive statistics, chi-square, and independent t-tests compared data between genders 
and student classification (undergraduate or graduate).  Knowledge is a dichotomous variable, 
and the independent t-test was used to find the difference in knowledge scores between genders, 
student classification, and vaccine uptake.  Although the uptake of the vaccine had three possible 
options, it was treated as a dichotomous variable to find a relationship in the independent 
variables. Since attitude was measured with a Likert-scale, it is a scale variable. Logistic 
regression was used to correlate knowledge between genders, student classification, and vaccine 
uptake. PAPM staging and factors associated with uptake are nominal variables, and Chi-square 
was used to measure their association with gender, student classification, and uptake. 
Results 
The total number of participants was 507 with a response rate of over 60% of all nursing 
students attending the fall semester of 2019. Several participants were omitted from the final 
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analysis for 1) identifying as being below the age of 18 (n = 1), 2) not answering more than half 
of the knowledge and attitude sections (n = 59), and 3) identifying as “Other” for the gender (n = 
1). The final number of surveys included in the data analysis was 447. One student did not 
answer a majority of the attitude questions and was removed for the attitude analysis (n = 446). 
Unanswered questions appeared to be missing at random, and data was not imputed for the 
knowledge section. If participants missed a question, it was assumed they did not know the 
answer and was considered incorrect. Data were imputed for the attitudes section with the mean 
score for each question.  
Demographics 
Demographic information included age, gender, student classification, ethnicity, 
engaging in preventative health care, HPV education, and HPV vaccination uptake. The age of 
the participants ranged from 18 to 62 years with a mean of 22.5 years (SD = 4.69). The majority 
of the participants reported being female (93.1%, n = 416), White (87.3%, n = 391), and 
undergraduate student students (84.1%, n = 376). Most of the respondents participated in 
routine, preventative health care (89%, n = 398). Of the 447 responses, 31.1% (n = 139) had 
zero HPV vaccinations and 68.9% (n = 308) having at one or more doses (see Table 1 for 
demographics). 
Knowledge Results 
The maximum knowledge score in this survey was 19. Knowledge scores for the 
participants ranged from three to 19 with a mean knowledge score of 14.6 (SD = 2.39). The 
majority of the participants (61.7%, n = 311) had a high knowledge level of HPV followed by 
moderate levels (30%, n = 134) and low levels (0.4%, n = 2) (see Table 2 for knowledge scores 
for all participants). The top three questions students answered incorrectly were 1) “HPV is 
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transmitted by skin-to-skin contact,” 2) “Most adults are infected with HPV,” and 3) “There is a 
routine HPV test for men.”  These questions were related to transmission, prevalence, and 
screening guidelines. 
The independent t-test showed there were no significant differences between the 
knowledges score for males (M = 14.84, SD = 2.62) and females (M = 14.60, SD =2.37), t(445)= 
.544, p = .59, d  = 0.96 (see Table 3 for t-Test for Independent Groups – Knowledge).  Graduate 
students (M = 15.6, SD = 2.46) had a higher mean knowledge score than undergraduate students 
(M = 14.4, SD = 2.34), t(444) = -3.92, d  = -.5, p < .001. Furthermore, there were some 
statistically significant differences on certain items between undergraduate and graduate 
students. More undergraduate students incorrectly answered items related to transmission, cure, 
and cancer caused by HPV compared to graduate students.  Nearly 47.1 % (n = 177) of 
undergraduate students knew that HPV is transmitted by skin-to-skin contact, 2 (1, N = 446) = 
4.87,  = .1, p = .027. Undergraduates (68.6%, n = 258) were also more likely to believe that 
there is no cure for HPV, 2 (1, N = 446) = 4.67,  = .1, p = .031. Finally, a smaller percentage 
of undergraduate students were aware that HPV could cause oral cancer (58.2%, n = 219) and 
anal cancer (68.4%, n = 257) than graduate students (see Table 4 for Knowledge – Correct 
Answers).  
The mean knowledge score was similar between those who were unvaccinated (M = 
14.53, SD = 2.58) and those who had received at least one vaccination (M = 14.65, SD = 2.31), 
t(445) = -4.78, d =. -.049, p = 0.63. Additionally, there were no differences in having HPV 
education (M=14.3, SD = 2.33) or not having HPV education (M = 14.7, SD = 2.41), t(444) = -
1.29, d = -.17, p = .2 (see Table 3 for t-Test for Independent Groups – Knowledge).  
Attitude Results 
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The mean attitude score for all participants was 91.2 (SD = 9.99) and ranged from 36 to 
110. A low numeric attitude score represented a more negative attitude towards HPV and HPV 
vaccination. A higher numeric attitude score represented a more positive attitude. The majority 
of participants had a high attitude score (61.7%, n = 276) followed by moderate levels (37.8%, n 
= 169) and low levels (0.4%%, n = 2). Most respondents had a high level of perceived 
susceptibility (97.1%, n = 434) and a moderate level of personal and social concerns towards 
HPV and vaccination (91.9%, n = 411). The majority of participants had high levels of 
confidence in vaccine safety (67.2%, n = 300) and vaccine efficacy (82.6%, n = 369) (see Table 
5 for attitude scores for all participants). 
Unvaccinated participants (M = 87.3, SD = 12.1) had a lower mean attitude score (M = 
93, SD = 8.28), t(445) = -5.02, d = -.055,  p < .001. There were no differences between the 
overall attitude scores of males (M = 89.2, SD = 8.2) and females (M = 91.4, SD = 10.1), t(445) = 
-1.18, D = -.024. p = .24 and in undergraduate (M = 91.3, SD =9.85) and graduate students (M = 
90.8, SD = 10.54), t(444) = .42, d = -.049, p = .67.  Attitude levels were not associated with 
having HPV education (M = 91.5, SD = 9.76) or not having HPV education (M = 89.6, SD = 
10.72), t(445) = -1.61, d = .19, p = .11 (see Table 6 for t-Test for Independent Groups – 
Attitudes). 
Chi-square analysis revealed differences on several items in those who “somewhat 
agreed” or “strongly agreed” on an item and participants who did not. Male students (n = 18, 
58.1%) were less likely to agree that HPV would be a severe threat to their health than females 
(n = 313, 75.2%), 2 (1, N = 446) = 4.43,  = .1, p = .04. There were no significant differences 
between undergraduate and graduate students on any item (see Table 7 for Attitudes – Percent 
“Strongly Agree” and “Somewhat Agree”).  
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Uptake 
 Participants age 18 to 20 (37.3%, n = 115) and age 21 to 29 (58.8%, n = 181) reported 
higher rates of vaccination compared to participants age 30 or older (3.9%, n = 12) (see Table 1).   
There were several statistically significant results with the chi-square analysis for uptake. 
Between genders, more females (71.2%, n = 295) had at least one HPV vaccination compared to 
males (38.7%, n = 12), 2 (1, N = 447) = 14.17,  = .18, p <.001. Those who had HPV education 
(85.4%, n = 263) were more likely to be vaccinated than those who did not have HPV education 
(14.6%, n = 45), 2 (1, N = 447) = 18.8,  = .21, p <.001. Likewise, students who participate in 
regular, preventative healthcare (71.6%, n  = 285) were more likely to be vaccinated that those 
who did not (46.9%, n = 23), 2 (1, N = 447) = 12.4,  = .17, p <.001. There were no differences 
in uptake between undergraduate (69.9%, n = 263) and graduate students (64.3%, n = 45), 2 (1, 
N = 446) = .86,  = -.045, p = .38. Vaccination (78.4%, n = 109) was associated with the belief 
vaccines do not cause problems, 2 (1, N = 447) = 44.4,  = -.32, p <.001.  The majority of 
unvaccinated participants 49.6% (n = 69) reported not being offered the vaccine, 2 (1, N = 447) 
= 152.3,   = -.58, p <.001 (see Table 8 for Chi-square Analysis for Independent Groups – 
Uptake). 
PAPM 
 The majority of males (78.9%, n = 15), females (57.5%, n = 69), undergraduate (61.9%, 
n = 70) and graduate students (52%, n = 13) who were not vaccinated reported never thinking 
about getting the HPV vaccination. One male (5.3%) and 16 females (13.3%) intended to get the 
vaccine within six months. Sixteen undergraduate students (13.3%) and two (8%) of graduate 
students intend to be vaccinated within six months. Twenty-three females (19.2%) and two 
graduate students (32%) decided against vaccination (see Table 9 for PAPM staging). Chi-square 
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analysis showed no significant association between those who did not participate in preventative 
health care and never thinking about the getting the vaccine, 2 (1, N = 139) = 2.14,  = .12, p = 
.21 (see Table 10 for Chi-square Analysis for Preventative Care and Never Getting the Vaccine). 
Factors Associated with Vaccination  
 Logistic regression was completed to indicate factors associated with vaccination status. 
The Hosmer and Lemeshow Test confirmed a good fit, 2 (6, N = 447) = 8.36, p = .21).  This 
model predicted 70.5% of the vaccination statuses in this study. Significant factors for 
vaccination were provider offered (p = <.001), family (p = <.001), belief the vaccine does not 
cause problems (p = <.001), belief the virus causes problems (p = .047), and no one offered the 
vaccine (p = <.001). More females (68.3%, n =  284) reported that providers recommended the 
vaccine to them than males (29%, n = 9), 2 (1, N = 447) = 17.69,  = .21, p = <.001. Of the 
vaccinated participants, 97.2% (n=172) reported family influence as a factor to being vaccinated. 
Participants were 39.6 times more likely to get the vaccine if their family encouraged them and 
10.6 times more likely if a provider offered it to them. A friend’s recommendation was not 
statistically significant as a factor to vaccination (see Table 11 for Factors Associated with 
Vaccination). 
Discussion 
 The purpose of this scholarly project was to evaluate HPV knowledge and attitudes, and 
their association to vaccination uptake in college nursing students. This project expanded on a 
previous study by Bernard et al. (2017), which examined the effect knowledge and attitudes have 
on HPV vaccination uptake and added a focus of a specific population of college nursing 
students. The last study on the topic of HPV and nursing students was in 2013 and occurred in 
New Mexico (Schmotzer & Reding, 2013). This project and Barnard et al.’s (2017) study were 
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located in the South and used the PAPM model for its theoretical basis. All three studies differed 
in ethnicity, student classification, and the students’ disciplines of study. 
Nursing programs usually have a smaller percentage of males to females. Gender 
percentages among nursing students mirrored those in Schmotzer and Reding’s (2013) 
population of nursing students but differed from Barnard et al.’s (2017) population since they 
surveyed the entire campus. Ethnicity among this sample population was similar to the setting of 
the project and Barnard et al.’s (2017) population. Schmotzer and Reding’s(2013) study had an 
almost equal number of Hispanics and non-Hispanics attending the nursing school near the U.S.-
Mexico border 
 The majority of the nursing students had high knowledge levels (61.7%, n = 311), with 
only 0.4% having low knowledge levels. This finding differed from the project's hypothesis of 
the presence of low knowledge levels among nursing students and may be attributed to the 
medical and healthcare interests of the sample. Additionally, there has been a drive to increase 
HPV vaccination and education from primary care providers and media over the last several 
years. The majority of students (79.9%, n = 357) reported having HPV education before taking 
the survey. Undergraduate students generally begin receiving HPV education in their third or 
fourth year but may have received some HPV information earlier with the change in nursing 
curriculum at the university. Schmotzer and Reding’s (2013) study did not report the knowledge 
levels in their research, but the majority of the participants answered eight of the 19 (42.1%) 
knowledge questions incorrectly in the study. A survey of the general student body revealed 
moderate knowledge levels at the undergraduate level (Barnard et al., 2017).  Similar to Barnard 
et al.’s, (2017) study, most participants incorrectly answered questions on HPV transmission, 
prevalence, and screening guidelines. Undergraduate nursing students were more likely to miss 
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questions regarding transmission, cure, and cancer caused by HPV. The lack of knowledge in 
these areas may require nursing education to increase or reinforce this information. These facts 
are important in educating patients and preventing the spread of HPV. 
           Males and females had similar knowledge scores, which mirrored the parent study 
(Barnard et al., 2013). Schmotzer and Reding’s (2013) study did not look at the difference 
between males and females. Graduate students (M = 15.6, SD = 2.46) had a higher mean score 
than undergraduate students (M = 14.4, SD = 2.34), t(444) = -3.92, d=  -.5, p < .001. This finding 
was not unexpected since they were in an advanced nursing program to become NPs. 
Undergraduate students may have had some HPV education, but not to the extent of advanced 
nursing students. Knowledge was not affected by vaccination status or having previous HPV 
education.  
 Nursing students possessed high attitude levels (61.7%, n = 276). Further analysis 
revealed the majority of students had high levels of perceived susceptibility (97.1%, n = 434), 
moderate personal and social concerns (91.9%, n = 411), and high levels of confidence in 
vaccine safety (91.9%, n = 411) and efficacy (82.6%, n = 369). Due to their background and 
training in healthcare, it is expected for this population to have higher attitude levels compared 
with the general student population. The general student population had lower (moderate) levels 
of perceived risk as compared to this project’s evaluation of perceived susceptibility (Barnard et 
al., 2017). The previous nursing study did not examine attitudes and beliefs.  
           Nurses play a key role in the safety and optimization of the health of families and patients. 
For all nurses, the primary approach is to educate. This approach may begin with listening for 
any concerns and addressing those specific concerns with sound research regarding the risks and 
benefits of vaccination. Knowledge of HPV, consequences, prevention, vaccination 
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contraindications, and side effects will be helpful in alleviating the fears and concerns of parents 
and patients. This may happen formally in the clinic or informally in social settings or social 
media. NPs regularly counsel and order vaccinations for patients. NPs may begin the process of 
HPV vaccination through anticipatory guidance before the child reaches the age of nine allowing 
parents time to make a thoughtful, educated decision before the next well-child appointment.    
Although several factors influence the decision to vaccinate, attitude was associated with 
vaccination status (M = 93, SD = 8.28), t(445) = -5.02, d = -.055,  p < .001. There was no 
statistical difference between attitude and gender (p = .24), student classification (p = .67), or 
HPV education (p = .11). Gender differences in 12 questions were found in the previous study of 
the general student population, but only in one question for this project (Barnard et al., 2013). In 
both studies, men were less likely to agree that HPV would be “a severe threat to their health” as 
compared to females, similar to the previous study. A high percentage (96.3%, n = 426) 
understood that HPV could be transmitted without having signs or symptoms; however, men did 
not see themselves at risk. Presenting HPV vaccination as a form of herd immunity may be an 
effective method to increase uptake. Vaccination decreases health risks for the vaccine recipient 
but also protects future sexual partners. A nurse’s attitude toward vaccination can influence 
personal uptake of the vaccination but also a parent’s decision. If a nurse has a negative attitude 
towards vaccination, it can dissuade a parent from vaccinating, especially one who trusts the 
nurse’s medical opinion. 
The majority of the students (68.9%, n = 308) reported receiving at least one dose. This 
percentage is higher than previous studies ranging uptake from zero to 68% (Schmotzer & 
Reding, 2013; Richman, Maddy, Torres, & Goldberg, 2016; Barnard et al., 2017; Johnson & 
Ogletree, 2017). These statistics also include Schmotzer and Reding’s (2013) study in which 
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28.9% of nursing students reported being vaccinated against HPV. Similar to Barnard et al.’s 
(2013) study, more females (47.3%) reported having at least one vaccine dose. Participants 
(73.7% , n = 263) who had routine, preventative health care and previous HPV education 
reported to have at least one dose of the vaccination. This finding suggests that those who 
participate in preventative health care, whether it be having a primary care provider or going to 
the school clinic for routine checks or immunizations, are more likely to be vaccinated. As a 
healthy, young student, most of the general students may not see the need for primary care. 
Educating the importance of an annual check, preventative measures, and routine vaccination can 
decrease the disease and illness.   
A small percentage of vaccinated participants (14.6%, n = 45) indicated they did not have 
HPV education. These participants may have received the vaccination as part of their childhood 
immunizations and may or may not understand the purpose of the vaccine. Educating parents on 
HPV and the role of the vaccine can assist them in making informed vaccine decisions for their 
children. Older students were more likely to be unvaccinated, which may be attributed to vaccine 
being released in 2006 and the recent advancement in educating and awareness of HPV over the 
last several years. There were no differences in uptake between undergraduate and graduate 
students (p = .35).  
The PAPM model was used to describe the stage of change unvaccinated participants 
were occupied. The majority of unvaccinated males, females, undergraduate and graduate 
students reported being in Stage 1 (unawareness) and Stage 2 (unengaged) (60.4%, n = 84) or 
Stage 4 (decided against) (17.3%, n = 24). These higher rates of Stage 1 and 2 highlight the need 
to increasing awareness and education of HPV and risks and benefits of HPV vaccination among 
students.  This study possibly prompted participants in this group to begin thinking about 
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vaccination. Several students (12.2%, n = 17) intend to be vaccinated within the next six months. 
These students would benefit with information about HPV, vaccination, and accessing a 
provider. Although 24 students did decide against vaccination, emphasis on safe, sexual practices 
and routine pap screens are alternate recommendations nurses can educate these patients on 
limiting the spread of HPV. Despite the association between having preventative healthcare and 
uptake, there was no association between lack of preventative healthcare and “never thinking of 
vaccination” (p = .21). 
Stage 7 (maintenance) was not addressed in the survey. Aside from vaccination, other 
preventative measures for HPV are safe, sexual practices (condom and dental dam use). It is 
important to educate patients on the abstinence if genital warts are present, because the virus is 
more likely to be transmitted during this time. Although there is not a cure for genital warts, 
there are treatment options such as topicals and surgery. For females, routine pap tests are 
essential for early screening of HPV. Despite no recommendations for screening for HPV in 
males, men who have sex with men who are considered high-risk may consider periodic anal pap 
tests (CDC, 2015) 
 Consistent with the literature, provider recommendation was a significant factor for 
vaccination (Gilkey et al., 2016; Barnard et al., 2017; Kellogg et al., 2019). In this sample, the 
family influence was markedly significant. Participants were 39.6 times more likely to be 
vaccinated if the family recommended vaccination as compared to Barnard et al.’s (2017) finding 
of a 1.89 increased likelihood. Similar to Barnard et al.’s (2017) finding, participants in this 
sample were 10.6 times more likely to be vaccinated if a provider recommended the vaccine. 
When children are young, the medical decision making generally belongs to the parents. In the 
previous study, both provider and family/friends influence were factors to vaccination (Barnard 
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et al., 2017). Family and parental beliefs concerning vaccination certainly play a significant role 
in the health of a young child. Young adults may not recall a provider's recommendation or 
education on HPV from when they are young. Parents make the ultimate decision for young 
children and adolescents' vaccinations. It is part of the nurse's role to educate the parents and 
patients. Discussing the vaccine as a cancer prevention method may highlight the importance of 
the vaccine to both parties.  
Practice Implications   
 Nurses play a key role in safety and optimizing the health of families and patients. For all 
nurses, the primary approach is to educate. This may begin with listening for any concerns and 
addressing specific worries with research and the risks and benefits of vaccination. Knowledge 
of HPV, consequences, prevention, vaccination contraindications and side effects will help 
alleviate the fears and concerns of parents. This may happen formally in the clinic or informally 
in social settings or social media. With the NPs’ scope of practice, they may regularly care for 
patients and order the HPV vaccine. NPs may begin the process of HPV vaccination through 
anticipatory guidance with families when a child is eight or nine years old. This allows parents 
time to make a thoughtful, educated decision before their next well-child appointment.   
           It is also important for nurses to not only be knowledgeable but also have a favorable 
attitude towards vaccination. Confidence in the safety and efficacy of the vaccine can affect 
parental decisions in vaccination. A positive attitude can make vaccination seem more favorable 
to parents and patients, especially in those who trust and value the medical opinion of the RNs 
and NPs at the clinic.   
The results of the study may assist nursing educators in the effectiveness of their HPV 
education in their program. The students of this program did have high knowledge levels, but 
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educators can emphasize transmission, prevalence, and screening guidelines. Knowledge and 
attitudes towards HPV and vaccination also have implications from a public health perspective. 
The benefits of the vaccine are health optimization, cost, reduction of possible emotional 
distress, and mitigation of viral transmission, warts, and cancer. Fourteen million people are 
infected yearly with HPV, and usually, HPV resolves without treatment (CDC, 2017). When it 
does not resolve, it can cause warts and cancer.  Uptake of the vaccine can prevent the spread of 
disease and decrease the risk of warts and cancer in an especially vulnerable community.  
Strengths and Limitations 
 A strength of this project included a high response rate and sample size. Over 60% (n 
= 507) of nursing students started the survey. This project had 447 surveys included in the 
analysis compared to the parent study (n = 383). As a replication study, this project was able to 
support the previous study. This study also included both undergraduate and graduate nursing 
students, instead of solely undergraduate students. To the project leader's knowledge, this was 
the second study to use the PAPM to assess college students' knowledge, attitudes, and uptake of 
the HPV vaccine. This project was the only study to address the knowledge gap concerning HPV 
and American nursing students since 2013. As future nurses and providers, providing accurate 
information and evidence about HPV gives patients, parents, and the community the means to 
make an informed decision about being vaccinated. 
           Limitations of this study were the use of cross-sectional design and a self-reported survey. 
The self-reported survey was not proctored; therefore, participants had the opportunity to search 
for the information on HPV while taking the survey, possibly skewing the data on knowledge. 
This was a convenience sample at a private, religious, liberal arts university of nursing students 
in the Southeastern U.S. Generalizability was limited because nursing students are assumed to 
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have more healthcare knowledge compared to the general college students. It also lacked 
generalizability to nursing students because the sample came from a private, religious university. 
This is not reflective of many schools of nursing in the United States. Although adapted from a 
previous study, this instrument was not tested for reliability and validity. Data may have been 
skewed with some participants being older or in a long-term, monogamous relationship and 
viewed this topic as inapplicable. Social desirability response bias may have been present as the 
target population was nursing students and answered questions in a manner congruent with 
health care's pro-stance on vaccination. Finally, this project did not ask questions on completion 
of all doses of the HPV vaccine. Some participants may have started the process and have 
forgotten or decided to stop the vaccinations. Although the data will show if they have received 
the vaccine, it does not indicate if they are up to date on HPV vaccinations. This project did not 
follow-up on student’s vaccination status or participation in preventative screening. 
Conclusion 
This replication deepened the insight into the knowledge, beliefs, and uptake of the HPV 
and HPV vaccination in undergraduate and graduate nursing students. This study also 
contributed to closing the gap in research concerning nursing students and HPV. This study 
supported that nursing students, who will be at the forefront of providing health care, have high 
levels of knowledge and positive attitudes toward HPV and HPV vaccination. Without 
minimizing concerns and worries for vaccination, nurses can educate parents on how the benefits 
outweigh the risks for vaccination. The use of the Precaution Adoption Process Model helped 
identify the stage of change the unvaccinated students resided. Developing appropriate 
interventions for each stage aids in uptake. Finally, from a public health perspective, increasing 
the uptake of vaccination decreases transmission and risk of warts and cancer in a community. 
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Figure 1: Precautionary Adoption Process Model (adapted from Weinstein, Sandman, and 
Blalock, 2008). 
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Table 1: Demographics 
 
Age  
Mean Age 
Range 
18-20 
21-29 
>30 
22.5 (SD=4.69) 
18 – 62 
37.1% (n = 166) 
55.9% (n = 250) 
6.9% (n = 31) 
Gender  
Male 
Female 
6.9% (31) 
93.1% (416) 
College Classification  
Undergraduate 
Graduate 
84.1% (n = 376) 
15.7% (n = 70) 
Ethnicity  
Caucasian 
African-American 
Hispanic 
Middle Eastern 
Asian 
Other 
87.3% (n = 391) 
2% (n = 9) 
3.4% (n = 15) 
1.6% (n = 7) 
3.4% (n = 15) 
2.2% (n = 10) 
Preventative Healthcare  
No  
Yes 
11% (n = 49)  
89% (n = 398) 
Vaccination Uptake  
No Vaccinations 
1 Dose 
2 or More doses 
31.1% (n = 139) 
17.2% (n = 77) 
51.7% (n = 231) 
> 1 Vaccination Dose  
Age 18-20 
Age 21- 29 
> Age 30 
37.3% (n = 115) 
58.8% (n = 181) 
3.9% (n = 12 
HPV Education  
No  
Yes 
20.1% (n = 90)  
79.9% (n = 357) 
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Table 2: Knowledge Scores for All Participants 
Knowledge  
Mean Knowledge Score 
Range 
Low 
Moderate 
High  
14.61 (SD =2.39) 
3 - 19 
.4% (n = 2) 
30% (n = 134) 
69.6% (n = 311) 
 
 
 
 
 
 
 
 
 
 
 
HPV VACCINATION 
 
47 
Table 3: t-Test for Independent Groups – Knowledge  
    Gender     
  Male Female df t d p  
  14.84 (2.62) 14.6 (2.37) 445 .544 .096 .59  
    Student 
Classification 
    
  Undergraduate Graduate df t d p  
Knowledge  
Mean (SD) 
 14.4 (2.34) 15.6 (2.46) 444 -3.92 -.50 <.001  
    Uptake     
  None >1 df t d p  
  14.53 (2.56) 14.65 (2.31) 445 -4.78 -.049 .63  
    HPV Education     
  Yes No df t d p  
  14.3 (2.33) 14.7 (2.41) 444 -1.29 -.17 .2  
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Table 4: Knowledge – Correct Answers 
Questions All  Gender     Student Classification     
             
   Male Female   
 
 
p   Undergrad Graduate  
 
p   
1. Genital warts 
are caused by 
HPV 
72%  
(n = 322) 
 80.6% 
 (n = 25) 
71.4%  
(n = 297) 
-.052 .37* 
 
 70.7% (n = 
266) 
78.6%  
(n = 55) 
.063 .18  
2. HPV can 
cause cervical 
cancer 
95.3%  
(n = 426) 
 90.3%  
(n = 28) 
95.7%  
(n = 398) 
.064 .17**  94.4% (n = 
355) 
100%(n = 70) .096 .058**  
3. Abnormal pap 
tests may 
indicate that a 
woman has 
HPV 
87.9%  
(n = 393) 
 96.8%  
(n = 30) 
87.3%  
(n = 363) 
-.077 .16**  87.8% (n = 
330) 
88.6%  
(n = 62) 
.009 1**  
4. HPV can 
cause penile 
cancer 
60.2%  
(n = 269) 
 58.1%  
(n = 18) 
60.3%  
(n = 251) 
.012  .80  58.5% (n = 
220) 
68.6%  
(n = 48) 
.075 .12  
5. HPV is 
transmitted by 
skin-to-skin 
contact 
49.2%  
(n = 220) 
 54.8%  
(n = 17) 
48.8%  
(n = 203) 
-.031  .52  47.1% (n = 
177) 
61.4%  
(n = 43) 
.1 
 
.027  
6. HPV infects 
both men and 
women 
equally 
61.1%  
(n = 273) 
 58.1%  
(n = 18) 
61.3% ( 
n = 255) 
.017 .72  61.2% (n = 
230) 
60%  
(n = 42) 
-.009 .85  
7. HPV is 
sexually 
transmitted 
96.6%  
(n = 432) 
 96.8%  
(n = 30) 
96.6%  
(n = 402) 
-.002 1**  96.3% (n = 
362) 
98.6%  
(n = 69) 
.046 .48**  
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8. I can transmit 
HPV even if I 
don't have 
symptoms 
95.3%  
(n = 426) 
 96.8% 
 (n = 30) 
95.2%  
(n = 396) 
-.019 1**  94.9%  
(n = 357) 
97.1%  
(n = 68) 
.038  .55**  
9. Most persons 
with HPV 
have no 
visible signs 
or symptoms 
91.1% 
 (n = 407) 
 93.5%  
(n = 29) 
90.9%  
(n = 378) 
-.024 1**  90.7%  
(n = 341) 
92.9%  
(n = 65) 
.028 .72*  
10. HPV can lay 
dormant in the 
body for years 
without 
symptoms 
96%  
(n = 429) 
 96.8%  
(n = 30) 
95.9%  
(n = 399) 
-.011 1**  95.5% 
 (n = 359) 
98.6% ( 
n = 69) 
.057 .33**  
11. There is a 
vaccine 
available to 
prevent HPV 
infection 
94.6%  
(n = 423) 
 100%  
(n = 31) 
100%  
(n = 394) 
.013 .68  94.1%  
(n = 354) 
98.6%  
(n = 69) 
.073 .15**  
12. There is no 
cure for HPV 
70.5%  
(n = 315) 
 74.2%  
(n = 23) 
70.2%  
(n = 292) 
-.022 .79*  68.6%  
(n = 258) 
81.4%  
(n = 57) 
.1 .031  
13. Most adults 
are infected 
with HPV 
38%  
(n = 170) 
 38.7%  
(n = 12) 
38%  
(n = 158) 
-.004 .94  37.2%  
(n = 140) 
42.9% 
 (n = 30) 
.042 .37  
14. HPV infection 
among men is 
rare 
80.1% 
 (n = 358) 
 74.2%  
(n = 23) 
80.5%  
(n = 335) 
.040 .54*  79.8%  
(n = 300) 
81.4%  
(n = 57) 
.015 .75  
15. HPV can 
cause oral and 
throat cancer 
61.5% 
 (n = 275) 
 67.7% 
 (n = 21) 
61.1%  
(n = 254) 
-.035 .46  58.2%  
(n = 219) 
78.6%  
(n = 55) 
.152 .001  
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16. HPV can 
cause anal 
cancer 
70.2% 
 (n = 314) 
 64.5%  
(n = 20) 
70.7% 
 (n =294) 
.034 .47  68.4%  
(n = 257) 
80%  
(n = 56) 
.093 .05  
17. There is a 
routine HPV 
test for men 
55.7%  
(n = 249) 
 61.3%  
(n = 19) 
55.3%  
(n = 230) 
-.031 .52  54.3%  
(n = 204) 
64.3%  
(n = 45) 
.073 .12  
18. There are 
many types of 
HPV 
91.1%  
(n = 407) 
 93.5%  
(n = 29) 
90.9% 
(n = 378) 
-.024 1**  91%  
(n = 342) 
91.4%  
(n = 64) 
.006 1*  
19. The HPV 
vaccine covers 
certain HPV 
strains 
94.9% 
 (n = 424) 
 93.5%  
(n = 29) 
95% 
(n = 395) 
.016 .67**  93.9%  
(n = 353) 
100%  
(n = 70) 
.10 .035**  
* Yates continuity correction 
**Fisher’s Exact Test 
  = effect size 
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Table 5: Attitude Scores for All Participants 
Attitudes   
Mean Score 
Range 
Low 
Moderate 
High 
91.2 (SD = 9.99) 
36 - 110 
0.4% (n = 2) 
37.8% (n = 169) 
61.7% (n = 276) 
Perceived Susceptibility  
Mean Score 
Range 
Low 
Moderate 
High 
41.63 (SD = 5.58) 
18 - 50 
0.2% (n = 1) 
2.7% (n = 12) 
97.1% (n = 434) 
Concerns  
Mean Score 
Range 
Low 
Moderate  
High 
22.1 (SD = 4.16) 
7 - 33 
4.3% (n = 19) 
91.9% (n = 411) 
3.8% (n = 17) 
Vaccine Safety  
Mean Score 
Range 
Low 
Moderate 
High 
19.2 (SD = 3.86) 
5 - 25 
0.9% (n = 4) 
32% (n = 143) 
67.2% (n = 300) 
Vaccine Efficacy  
Mean 
Range 
Low 
Moderate 
High 
4.2 (SD = 1) 
1 – 5 
6.9% (n = 31) 
10.5% (n = 47) 
82.6% (n = 369) 
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Table 6: t-Test for Independent Groups – Attitudes 
 
    Gender     
  Male Female df t d p  
  89.2 (8.2) 91.4 (10.1) 445 -1.18 -.024 .24  
    Student 
Classification 
    
  Undergraduate Graduate df t d p  
Attitudes 
Mean (SD) 
 91.3 (9.85) 90.8 (10.54) 444 .42 -.049 .67  
    Uptake     
  None >1 df t d p  
  87.3 (12.1) 93 (8.28) 198.3 -5.02 -.055 <.001  
    HPV Education     
  Yes No df t d p  
  91.5 (9.76)  89.6 (10.72) 445 -1.61 .19 .11  
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Table 7: Attitudes - Percent “Strongly Agree” and “Somewhat Agree” 
Questions All   Gender 
(N=447) 
   Student Classificati
on (N =. 
446) 
   
             
   Male Female  p  Undergrad Graduate  p  
1. I am at risk for 
getting HPV 
17.4%  
(n = 78) 
 12.9%  
(n = 4) 
17.8% 
 (n = 74) 
.03 .63**  18.1%  
(n = 68) 
14.3%  
(n = 10) 
-.036 .44  
2. I am likely to 
contract the 
HPV virus in 
my lifetime 
26.6% 
 (n = 119) 
 22.6%  
(n = 7) 
26.9% 
 (n = 112) 
.03 .75*  27.1%  
(n = 102) 
24.3% (n = 
17) 
-.023 .62  
3. HPV would be 
a severe threat 
to my health 
74%  
(n = 331) 
 58.1% 
 (n = 18) 
75.2% 
 (n = 313) 
.1 .04  75.5% 
 (n = 285) 
65.7% 
 (n = 46) 
-.084 .077  
4. HPV would be 
a serious 
threat to my 
sex life 
72.3%  
(n = 323) 
 64.5%  
(n = 20) 
72.8%  
(n = 303) 
.05 .32  72.6%  
(n = 273) 
70% 
 (n = 49) 
-.021 .65  
5. HPV would 
make it 
difficult to 
find a long-
term partner  
58.8% 
 (n = 263) 
 54.8%  
(n = 17) 
59.1% 
 (n = 246) 
.02 .64  60.4% 
 (n = 227) 
51.4% 
 (n = 36) 
-.066 .16  
6. I would tell 
my sexual 
partner if I 
had HPV 
93.3%  
(n = 417) 
 93.5 %  
(n = 29) 
93.3%  
(n = 388) 
-.003 1**  93.9%  
(n = 353) 
91.4%  
(n = 64) 
-.036 .62*  
7. If I had HPV I 
would be at 
risk for 
transmitting it 
to others  
87.7%  
(n = 392) 
 83.9%  
(n = 26) 
88%  
(n = 363) 
.032 .7*  87.5% 
 (n = 329) 
90%  
(n = 63) 
.028 .7*  
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8. I would need 
the HPV 
vaccine if I 
had a high 
number of 
sexual 
partners 
89% 
 (n = 398) 
 90.3% 
 (n = 28) 
88.9%  
(n = 370) 
-.01 1 ***  88.8%  
(n = 334) 
91.4%  
(n = 64) 
.031 .66*  
9. I would need 
the HPV 
vaccine if I 
had multiple 
sexual 
partners 
90.2%  
(n = 403) 
 87.1%  
(n = 27) 
90.4%  
(n = 376) 
.03 .53**  90.2% 
 (n = 339) 
91.4%  
(n = 64) 
.016 .91*  
10.  I would need 
the HPV 
vaccine if I 
had a family 
history of 
cervical 
cancer 
84.8% 
 (n = 379) 
 71% 
 (n = 22) 
85.8%  
(n = 357) 
.11 .05*  84.8% 
 (n = 319) 
85.7%  
(n = 60) 
.009 .85  
11. I would need 
the HPV 
vaccine if I 
regularly used 
a condom 
when 
engaging in 
sexual activity 
78.7%  
(n = 352) 
 74.2%  
(n = 23) 
79.1% 
 (n = 329) 
.03 .68*  79%  
(n = 297) 
78.6%  
(n = 55) 
-.004 .94  
12. I would need 
the HPV 
vaccine if I 
engaged in 
80.3%  
(n = 359) 
 67.7%  
(n = 21) 
81.3%  
(n = 338) 
.13 .07  81.6% 
 (n = 305) 
74.3% 
 (n = 52) 
-.068 .15  
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sexual activity 
with a same 
sex partner  
13. I would need 
the HPV 
vaccine if I 
had a steady 
long-term 
partner 
71.4% 
 (n = 319) 
 58.1%  
(n = 18) 
72.4%  
(n = 301) 
.08 .09  71.8%  
(n = 270) 
70%  
(n = 49) 
-.015 .77  
14. I would need 
the HPV 
vaccine if I 
smoked 
48.8%  
(n = 218) 
 54.8%  
(n = 17) 
48.3% 
 (n = 201) 
-.03 .48  49.2% 
 (n = 185) 
47.1%  
(n = 33) 
-.015 .75  
15. I would need 
the HPV 
vaccine if I 
engaged in 
sexual activity 
with a partner 
of the 
opposite sex 
87%  
(n = 389) 
 83.9% 
 (n = 26) 
92.5% 
 (n = 363) 
.08 .17*  87.5%  
(n = 329) 
85.7% 
 (n = 60) 
-.019 .68  
16. I would need 
the HPV 
vaccine if I 
engage in 
unprotected 
sexual activity  
91.9%  
(n = 411) 
 83.9%  
(n = 26) 
92.8%  
(n = 385) 
.084 .085**  91.8%  
(n = 345) 
94.3%  
(n = 66) 
.034 .63**  
17. The HPV 
vaccine has 
significant 
side effects 
27.7%  
(n = 124) 
 22.6% 
 (n = 7) 
28.1%  
(n = 117) 
.031 .65*  29% 
 (n = 109) 
21.4%  
(n = 15) 
-.061 .2  
18. The HPV 
vaccine was 
68.9%  
(n = 308) 
 54.8%  
(n = 17) 
70% 
 (n = 291) 
.083 .08  68.4%  
(n = 257) 
72.9%  
(n = 51) 
.035 .45  
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thoroughly 
tested 
19. The HPV 
vaccine is 
likely to cause 
health 
problems 
21.9% 
 (n = 98) 
 25.8%  
(n = 8) 
21.6%  
(n = 90) 
-.026 .75*  23.9%  
(n = 89) 
12.9%  
(n = 9) 
-.095 .064*  
20. I could get 
HPV from the 
vaccine 
11%  
(n = 49) 
 3.2%  
(n = 1) 
 
11.5%  
(n = 48) 
.068 .23**  11.4%  
(n = 453 
8.6%  
(n = 6) 
-.033 .62*  
21. I am 
concerned my 
family would 
find out if I 
got the HPV 
vaccine 
14.8% 
 (n = 66) 
 19.4% 
(n = 6) 
14.4%  
(n = 60) 
-.04 .63*  15.7%  
(n = 59) 
8.6%  
(n = 6) 
-.073 .17*  
22. I am 
concerned my 
friends would 
find out if I 
got the HPV 
vaccine 
12.5%  
(n = 56) 
 16.1%  
(n = 5) 
12.3% 
 (n = 51) 
-.04 .73*  13.6%  
(n = 51) 
7.1% 
(n = 5) 
-.07 .19*  
23. The HPV 
vaccine is an 
effective way 
to prevent 
HPV infection 
82.6%  
(n = 369) 
 77.4%  
(n = 24) 
82.9%  
(n = 345) 
.04 .59*  82.2% 
 (n = 309) 
85.7%  
(n = 60) 
.034 .47  
24. Overall, the 
HPV vaccine 
is safe 
84.8%  
(n = 379) 
 77.4%  
(n = 24) 
85.3%  
(n = 355) 
.06 .36  84%  
(n = 316) 
90%  
(n = 63) 
.061 .27  
* Yates continuity correction 
**Fisher’s Exact Test 
 (Phi) = effect size 
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Table 8: Chi-square Analysis for Independent Groups – Uptake  
   Belief Vaccine Causes Problems    
Uptake 
(None) 
 Yes 
78.4% (n = 69) 
No 
97.4% (n = 300) 
 
.58 
p 
<.001 
 
   Offered (in general)    
  Yes 
2.3%% (n = 7) 
No 
49.6% (n = 69) 
 
-.58 
p 
<.001 
 
   Gender    
  Male 
38.7% (n = 12) 
Female 
71.2% (n = 296) 
 
-.18 
p 
<.001 
 
   Student Classification    
  Undergraduate 
69.9% (n = 263) 
Graduate 
64.3% (n = 45) 
 
-.045 
p 
.35 
 
   Preventative Healthcare    
Uptake  
(>1 dose) 
 Yes 
71.6% (n = 285) 
No 
46.9% (n = 23) 
 
.17 
p 
<.001 
 
   HPV Education    
  Yes 
73.7% (n = 263) 
No 
50% (n = 45) 
 
-.21 
p 
<.001 
 
   Provider Offered    
  Yes 
88.4% (n = 259) 
No 
31.8% (n = 49) 
 
.58 
p 
<.001 
 
   Belief Virus Causes Problems    
  Yes No  p  
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26.9% (n = 83) 73.1% (n =225) .16 .001 
   Belief Vaccine Causes Problems    
  Yes 
21.6% (n = 30) 
No 
78.4% (n = 109) 
 
-.32 
p 
<.001 
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Table 9: PAPM Staging 
Stage All  Gender   Student Classification  
         
   Male Female  Undergrad Graduate  
Stages 1 and 2:  
I never seriously thought about 
getting the HPV vaccination. 
60.4% (n = 84) 
 
 78.9% (n = 15) 57.5% (n = 69)  61.9% (n = 70) 52% (n = 13)  
Stage 3: 
I have seriously thought about 
getting the HPV vaccination but 
have not thought about it in past 6 
months. 
10.1% (n =14) 
 
 10.5% (n = 2) 10% (n = 12)  10.6% (n = 12) 8% (n = 2)  
Stage 4: 
I have seriously thought about 
getting the HPV vaccination but 
decided against it. 
17.3% (n = 24) 
 
 5.3% (n = 1) 19.2% (n = 23)  14.2% (n = 16) 32% (n = 8)  
Stage 5: 
I am seriously thinking about 
getting the HPV vaccination 
sometime within the next 6 
months. 
10.8% (n = 15) 
 
 5.3% (n = 1) 11.7% (n = 14)  11.5% (n = 13) 8% (n = 2)  
Stage 5, transitioning to Stage 6: 
I plan to get the HPV vaccination 
within the next month. 
1.4% (n = 2)  0% (n = 0) 1.7% (n = 2)  1.8% (n = 2) 0% (n = 0)  
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Table 10: Chi-square Analysis for Preventative Care and Never Getting the Vaccine 
 Have Never Thought about 
Getting the HPV Vaccine 
Have Thought about Getting 
HPV Vaccine 
Preventative Healthcare  22.6% (n = 19) 12.7% (n = 7) 
No Preventative Healthcare 77.4% (n = 65) 87.3% (n = 48) 
Pearson Chi-square: 2 (1, N = 139) = 2.14,  = .12, p = .21 (Yates)
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Table 11: Factors Associated with Vaccination 
      95% CI for 
Odds Ratio 
 
 
 
 
  (SE) Wald 
Statistic 
df p Lower Odds 
Ratio 
Upper  
Provider 
Offered 
2.357 
(.412) 
32.807 1 .000 4.715 10.564 23.669  
Family Wanted 3.678 
(.623) 
34.907 1 .000 11.680 39.566 134.032  
Friends Wanted -.262 
(1.240) 
.045 1 .832 .068 .769 8.736  
Belief the 
Vaccine Causes 
Problems 
-2.528 
(.688) 
.688 1 .000 .021 .080 .307  
Belief the Virus 
Causes 
Problems 
.873 (.440) .440 1 .047 1.011 2.394 5.668  
No One Offered -2.043 .589 1 .001 .041 .130 .411  
Constant -.997 .400 1 .013  .369   
CI = Confidence interval; Hosmer & Lemenshow 2 (6, N = 447) = 8.358, p = .21; Nagelkerke 
R2  = .501; Cox & Snell R2 = .71. 
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Appendix A: Letter of Invitation 
October 1, 2019 
Dear Belmont Nursing Students, 
 
We are writing to ask for your help by participating in a short, online survey on human papilloma 
virus (HPV) and HPV vaccination. The purpose of this project is to assess knowledge and 
concerns of HPV and HPV Vaccination in nursing students. This survey does not ask questions 
about your personal or sexual history.  
 
Undergraduate and graduate participants will have the opportunity to win one of four $25 
Amazon gift cards through a randomized drawing. All nursing students, 18 years and older, are 
eligible to participate. The survey should take approximately 5 minutes to complete. Your 
participation is voluntary, and your responses will be kept confidential and anonymous. If you 
choose to participate you may choose to discontinue participation at any time and you may 
choose any of the survey questions that you do not wish to answer.  Your completion of the 
survey and returning it to the investigators indicates your consent to participate in this study. If 
you have any questions, please contact Joanna Plumb via the contact information below.  
 
You can access the online, mobile -friendly survey through these options: 
Survey on HPV and HPV Vaccination 
Or copy and paste the URL code into your internet browser: 
https://belmont.az1.qualtrics.com/jfe/form/SV_domFUFv6m57F2UR 
Or scan the QR code 
 
Thank you for your participation in this survey, 
 
Joanna Plumb  
DNP Candidate 
Belmont School of Nursing 
e: joannamarie.plumb@belmont.edu 
cell: (615) 618-0412 
 
 
 
 
Dr. Martha Buckner  
Associate Dean of Nursing  
Belmont School of Nursing 
 
 
Dr. Jeannie Giese 
Faculty-Sponsor, Associate Professor 
Belmont School of Nursing, Inman 203-D 
e: jeannie.giese@belmont.edu
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Appendix B: QR Code 
 
 
 
HPV and HPV Vaccine Survey 
 
You may access the survey through the link sent to your 
school email 
OR scan this QR Code: 
 
Thank you for your participation! 
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Appendix C: HPV Vaccination Survey 
Demographics 
Q1 Are you 18 or older? 
o Yes  
o No  
 
Q2 How old are you? Please enter a 2-digit whole number.  
 
Q3 Are you an undergraduate or graduate student? 
o Undergraduate  
o Graduate  
 
Q4 Have you had education on HPV or HPV vaccination? 
o Yes  
o No  
 
Q5 What is your ethnicity? 
o Caucasian  
o African American  
o Hispanic  
o Middle Eastern  
o Asian  
o Other  
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Q6 Are you receiving routine, preventative health care? 
o Yes  
o No 
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Knowledge 
Q7 Please answer the following true or false questions regarding HPV and the HPV vaccine. 
 
 
Start of Block: Please Rate 
 
End of Block: True or False 
 
Start of Block: Please Rate 
End of Block: True or False 
 
Start of Block: Please Rate 
 
Start of Block: Please Rate 
 True False 
Genital warts are caused by 
HPV  o  o  
HPV can cause cervical 
cancer  o  o  
Abnormal pap tests may 
indicate that a woman has 
HPV  
o  o  
HPV can cause penile cancer  o  o  
HPV is transmitted by skin-
to-skin contact  o  o  
HPV infects both men and 
women equally  o  o  
HPV is sexually transmitted  o  o  
I can transmit HPV even if I 
don't have symptoms  o  o  
Most persons with HPV have 
no visible signs or symptoms  o  o  
HPV can lay dormant in the 
body for years without 
symptoms  
o  o  
There is a vaccine available to 
prevent HPV infection  o  o  
There is no cure for HPV  o  o  
Most adults are infected with 
HPV  o  o  
HPV infection among men is 
rare  o  o  
HPV can cause oral and throat 
cancer  o  o  
HPV can cause anal cancer  o  o  
There is routine HPV 
screening for men  o  o  
There are many types of HPV  o  o  
The HPV vaccine covers 
certain HPV strains  o  o  
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Concerns and Opinions about HPV  
 
Q8 Please rate your concerns and opinions regarding HPV. 
 
 
Strongly 
agree 
Somewhat 
Agree 
Neutral 
Somewhat 
disagree 
Strongly 
disagree 
I am at high risk for 
getting HPV  o  o  o  o  o  
I am likely to contract 
the HPV virus in my 
lifetime  
o  o  o  o  o  
HPV would be a severe 
threat to my health  o  o  o  o  o  
HPV would be a serious 
threat to my sex life  o  o  o  o  o  
HPV would make it 
difficult to find a long-
term partner  
o  o  o  o  o  
I would tell my sexual 
partner if I had HPV  o  o  o  o  o  
If I had HPV I would be 
at risk for transmitting 
it to others  
o  o  o  o  o  
I would need the HPV 
vaccine if I had a high 
number of sexual 
partners  
o  o  o  o  o  
I would need the HPV 
vaccine if I had 
multiple sexual partners  
o  o  o  o  o  
I would need the HPV 
vaccine if I had a family 
history of cervical 
cancer  
o  o  o  o  o  
I would need the HPV 
vaccine if I regularly 
used a condom when 
engaging in sexual 
activity  
o  o  o  o  o  
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 Strongly 
agree 
Somewhat 
Agree 
Neutral 
Somewhat 
disagree 
Strongly 
disagree 
I would need the 
HPV vaccine if I 
engaged in sexual 
activity with a same 
sex partner   
o  o  o  o  o  
I would need the 
HPV vaccine if I had 
a steady long-term 
partner  
o  o  o  o  o  
I would need the 
HPV vaccine if I 
smoked  
o  o  o  o  o  
I would need the 
HPV vaccine if I 
engaged in sexual 
activity with a partner 
of the opposite sex  
o  o  o  o  o  
I would need the 
HPV vaccine if I 
engage in unprotected 
sexual activity   
o  o  o  o  o  
The HPV vaccine has 
significant side 
effects  
o  o  o  o  o  
The HPV vaccine 
was thoroughly tested  o  o  o  o  o  
The HPV vaccine is 
likely to cause health 
problems  
o  o  o  o  o  
I could get HPV from 
the vaccine  o  o  o  o  o  
I am concerned my 
family would find out 
if I got the HPV 
vaccine  
o  o  o  o  o  
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Q9 How many HPV vaccine doses have you received? 
o 0  
o 1  
o 2 or more  
 
Q10 Have you thought about getting the HPV vaccine? 
o I never seriously thought about getting the HPV vaccination.  
o I have seriously thought about getting the HPV vaccination but have not thought about it 
in past 6 months.  
o I have seriously thought about getting the HPV vaccination but decided against it.  
o I am seriously thinking about getting the HPV vaccination sometime within the next 6 
months  
o I plan to get the HPV vaccination within the next month.  
 
 
Strongly 
agree 
Somewhat 
Agree 
Neutral 
Somewhat 
disagree 
Strongly 
disagree 
I am concerned my 
friends would find 
out if I got the HPV 
vaccine  
o  o  o  o  o  
The HPV vaccine is 
an effective way to 
prevent HPV 
infection  
o  o  o  o  o  
Overall, the HPV 
vaccine is safe  o  o  o  o  o  
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Q11 Which factors influenced you to receive the vaccine or not to receive the vaccine? 
▢ Provider Offered Vaccine   
▢ Family wants you to get vaccine  
▢ Friends wants you to get vaccine   
▢ Belief that the vaccine causes health problems  
▢ Belief that the virus causes health problems  
▢ No one has offered the vaccine  
 
 
Q12 What is your gender? 
We recognize there are multiple genders, but due the nature of this study, we ask for your 
biological gender (sex you are born with).  
o Male  
o Female  
o Other ________________________________________________ 
 
 
 
 
 
 
 
 
 
